Use of dipyrone in hospitalized patients

Uso de dipirona en pacientes hospitalizados

Article Sidebar


PDF (Español (España)) FLIP

How to Cite
Moreno de Santacruz, R., Buitrago, C. Y., & Pérez Pérez, M. (2013). Use of dipyrone in hospitalized patients. Journal of Medicine and Surgery Repertoire, 22(3), 204–208. https://doi.org/10.31260/RepertMedCir.v22.n3.2013.773
Published: Sep 1, 2013
Doi
https://doi.org/10.31260/RepertMedCir.v22.n3.2013.773
Issue
Vol. 22 No. 3 (2013): July - September
Section
Research Article
License terms

   

Main Article Content

Rocío Moreno de Santacruz
Carmen Yaneth Buitrago
Margarita Pérez Pérez

Abstract

Dipyrone is an analgesic and antipyretic widely used in Colombia; It is considered in other countries as a harmful medicine. The objective of this work is to determine its use as an analgesic for the management of pain in a third level entity. Descriptive cross-sectional study, with a population of 240 adults who received treatment with dipyrone; The data sources are the clinical history, the consumption reported by pharmacy in 2011 and the monthly calculation of the defined daily doses. Statistical analysis of the information was carried out in Stata 10. This drug was found to be the first-line analgesic in the institution for the management of pain in the postoperative period, with a prescription dose higher than that established by WHO. We analyze the possible relationship with adverse reactions, which occurred in 52% of patients, such as hypotension (98%) and skin rash (2%). It is concluded that there is a need to adjust the dose to 3 g / day to observe the clinical effectiveness of the medication and the economic impact on the institution. Abbreviations: DDD, defined daily dose.

Keywords:

Downloads

Download data is not yet available.

Article Details

References

1. Arcila H, Barragán S, Borbolla J, Canto A, Castañeda G,et al . Consenso de un grupo de expertos mexicanos: Eficacia y seguridad del metamizol (Dipirona). Gac. Méd.Méx.2004; 140(1):99-101.

2. Hamerschlak N, Cavalcanti AB.. Neutropenia, agranulocytosis and dipyrone. Sao Paulo Med J. 2005 Sep 1;123(5):247-9.

3. Maj S, Lis Y. The incidence of metamizole sodium-induced agranulocytosis in Poland. J Int Med Res. 2002 Sep-Oct; 30(5):488-95.

4. Lemus I, Pinardi G, Schönhöfer P. Advierten sobre riesgos de la dipirona [Monografía en Internet]. Santiago, Chile: PadresOk; 2011 [citado 19 Jun 2013]. Disponible en: http://www.padresok.com/2011/01/advierten-sobre-riesgos-de-la-dipirona/

5. Kaufman DW, Kelly JP, Levy M, Shapiro S. The drug etiology of agranulocytosis and aplastic anemia. New York: Oxford University Press; 1991.

6. Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. The International Agranulocytosis and Aplastic Anemia Study. JAMA 256(13):1749-57.

7. Siles Gutiérrez M, Ávila Muñoz L, Gómez Juanes V. Sistema de codificación de principios activos y dosis diarias definidas del INSALUD [Monografía en Internet]. Madrid, España: INSALUD; 2002 [citado 19 Jun 2013]. Disponible en: http://www.ingesa.msssi.gob.es/fr/estadEstudios/documPublica/pdf/codificacion.pdf

8. Macías E, Ruiz A, Moreno E, Laffond E, Dávila I, Lorente F. Usefulness of intradermal test and patch test in the diagnosis of nonimmediate reactions to metamizol. Allergy. 2007 Dec;62(12):1462-4.

9. Vasen W, Fiorentino RM. Farmacovigilancia una herramienta poco utilizada. Medicina (Buenos Aires). 2006; 66(3): 257-62.

10. Guía internacional de indicadores de precios de medicamentos [Monografía en Internet]. Cambridge, Massachusetts: MSH; 2011 [citado 19 Jun 2013]. Disponible en: http://erc.msh.org/dmpguide/pdf/DrugPriceGuide_2011_sp.pdf

11. Tipos de estudio de utilización de medicamentos [Monografía en Internet]. Santiago, Chile: Universidad de Chile; 2011 [citado 19 Jun 2013]. Disponible en: http://mazinger.sisib.uchile.cl/repositorio/lb/ciencias_quimicas_y_farmaceuticas/arancibiaa01/articulo28/b.html

12. Farmacovigilancia [Monografía en Internet]. Bogotá: INVIMA; 2012 [citado 19 Jun 2013]. Disponible en: http://web.invima.gov.co/portal/faces/index.jsp?id=4575

13. OMS. Agranulocitosis asociada con la Dipirona. Ginebra: Organización Mundial de la Salud; 2008.

14. Blasco Segura P, Mariño E.L, Aznar Saliente M.T, Pol Yanguas E, Almiñana MA, Castels Molina M, Velasco Álvarez M.L. Desarrollo de un método observacional prospectivo de estudio de Errores de Medicación para su aplicación en hospitales. Farm Hosp. 2001; 25(5): 253-73.

15. Otero MJ, Domínguez-Gil A. Acontecimientos adversos por medicamentos: una patología emergente. Farm Hosp. 2000; 24:258-66.

16. Edwards JE, Messenger F, Faura C, Moore RA, McQuay HJ. Single dose dipyrone for acute renal colic pain. Cochrane Database Syst Rev. 2002;(4): CD003867.

17. Montoya GA, Vaca C, Parra MF. Detección de efectos secundarios asociados a la administración de tramadol y dipirona en un hospital de alta complejidad. Biomédica 2009 Jul-Sep; 29(3):369-81.

18. Schneider CH, Kasper MF, de Weck AL, Rolli H, Angst BD. Diagnosis of antibody mediated drug allergy. Pyrazolone and pyrazolidinedione crossreactivity relationship. Allergy .1987 Nov;42(8):597-603.

Citado por